Almirall SA

Almirall SA’s stock volatility and high P/E signal a risky investment, even as the Spanish pharma firm’s dermatology focus may limit growth amid fierce competition.

Almirall’s Phase‑3 ADorable‑1 trial shows lebrikizumab achieves 63% EASI‑75 and 44% IGA 0/1 in children, boosting investor confidence while its new Shanghai office accelerates global dermatology expansion.

Almirall’s CEO warns Europe’s pharma is fading, yet China’s approval of Seysara shows the company’s niche dermatology strengths—can it survive the decline?

Almirall SA, a Spanish pharmaceutical company, solidifies its position in the global market with a stable stock performance, robust financial standing, and a commitment to innovative treatments for dermatological and central nervous system condition…

Almirall SA reports strong Q1 2025 results, with 15% year-over-year sales growth and 35% increase in EBITDA, driven by success in European Dermatology and biologics portfolio.